SK Bioscience Reports 369.5 Billion KRW in Sales Last Year... Operating Loss Turned

SK Bioscience announced on the 31st that it recorded operating revenue of 369.56 billion KRW and an operating loss of 11.988 billion KRW for last year.

SK Bioscience Andong L-HOUSE exterior. [Photo by SK Bioscience]

Compared to 2022, sales decreased by 19.1%, and operating profit turned into a loss. The company explained the cause, stating, "There was an impact from the sales decline due to the transition to the COVID-19 endemic (periodic epidemic of infectious diseases)."

By quarter, in the fourth quarter of last year, sales were 90.64 billion KRW, with an operating loss of 8.427 billion KRW. Compared to the same period last year, sales decreased by 35.4%, and operating profit turned into a loss. A representative from SK Bioscience said, "Sales decreased compared to the same period last year due to the absence of sales from the COVID-19 vaccine 'Skycovione'," adding, "The supply of Novavax's variant-adapted vaccine, the resumption of the influenza vaccine 'Skycellflu,' and the strong performance of the shingles vaccine 'Skyzoster' partially offset the sales decline."

This content was produced with the assistance of AI translation services.